| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/06/2005 | CA2541506A1 Immunogenic compostion and method of developing a vaccine based on psoralen inactivated hiv |
| 05/06/2005 | CA2541501A1 Immunogenic composition and method of developing a vaccine based on factor h binding sites |
| 05/06/2005 | CA2541497A1 Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site |
| 05/06/2005 | CA2541492A1 Immunogenic composition and method of developing a vaccine based on fusion protein |
| 05/06/2005 | CA2541117A1 Lipophilic drug delivery vehicle and methods of use thereof |
| 05/06/2005 | CA2540539A1 A mixture for transdermal delivery of low and high molecular weight compounds comprising an ethoxylated oil |
| 05/06/2005 | CA2539845A1 Methods and compositions for treating erectile dysfunction |
| 05/06/2005 | CA2539650A1 Skin care and cleansing compositions containing oil seed product |
| 05/05/2005 | US20050096637 Sensing food intake |
| 05/05/2005 | US20050096509 Nanotube treatments for internal medical devices |
| 05/05/2005 | US20050096479 Novel succinate salt of O-desmethyl-venlafaxine |
| 05/05/2005 | US20050096397 Adding trifluoroacetic acid dropwise to a solution of dimethylphenylsilane and (S)-amino-1-(2,5-dimethoxy-phenyl)-1-propanone, the amino group of which is protected, for example, with a methoxycarbonyl group; reduction; deprotecting; salt formation |
| 05/05/2005 | US20050096391 Particulate or in solid dosage forms; a combination of fenofibrate and HMG CoA reductase inhibitor rosuvastatin or a pharmaceutically active salts, upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCrosuvastatin) of between 150 to 12,000 |
| 05/05/2005 | US20050096390 Compositions comprising fenofibrate and pravastatin |
| 05/05/2005 | US20050096388 Compositions and methods for treating or preventing diseases of body passageways |
| 05/05/2005 | US20050096371 Topical pharmaceutical compositions |
| 05/05/2005 | US20050096365 Pharmaceutical compositions with synchronized solubilizer release |
| 05/05/2005 | US20050096340 lipophilic derivatives of paclitaxel, camptothecin, docetaxel or derivatives thereof; tocopherol succinate paclitaxel for example; emulsions for drug delivery, treating cancer; increased plasma elimination half-life compared to the parent therapeutic drug |
| 05/05/2005 | US20050096314 Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| 05/05/2005 | US20050096296 Solubility of drugs is enhanced with solubilizers for drugs such as pioglitazone, zafilukast, simvastatin, atarvastin or fenofifrate |
| 05/05/2005 | US20050096290 Treatment of diseases with aptamers with inverted nucleotide capped ends for treatment of neovascularization related diseases like age related macular degeneration |
| 05/05/2005 | US20050096287 Enhance delivery of oligonucleotides, nucleosides, nucleic acids by injection or applying on skin a solution in water |
| 05/05/2005 | US20050095641 Methods and materials for detecting genetic material |
| 05/05/2005 | US20050095363 Method and device for producing products in web form |
| 05/05/2005 | US20050095304 Composition and method for smoke detoxification |
| 05/05/2005 | US20050095301 Spherical core and coating of stabilizing antioxidant and lipophilic nutrient comprising lutein, lutein esters, alpha-carotene, beta-carotene, zeaxanthin, zeaxanthin esters, xanthophyll, astaxanthin, tocopherols, tocotrienols, plant stanols or phytosterols and/or lycopene; diets, anticarcinogenic agents |
| 05/05/2005 | US20050095300 Controlled release analgesic suspensions |
| 05/05/2005 | US20050095299 Administering non-steroidal antiinflammatory drugs such as ibuprofen, or acetaminophen via a liquid suspension; particle core with enteric and insoluble polymer coatings; immediate and sustained release dosages |
| 05/05/2005 | US20050095298 Three dimensionally crosslinked agarose bead with grass pollen covalently bound; immunotherapy, vaccines, diagnosis |
| 05/05/2005 | US20050095297 Nanoparticulate formulations of fenofibrate |
| 05/05/2005 | US20050095295 Therapeutic system for the controlled release of active ingredients |
| 05/05/2005 | US20050095294 Modafinil modified release pharmaceutical compositions |
| 05/05/2005 | US20050095293 Bioavailability of drug independent of gastric pH; core comprised of water soluble acid(s) of tartaric acid, fumaric acid, succinic acid, citric acid, malic acid, glutamic acid, and/or aspartic acid or salts; acid resistance; drug delivery |
| 05/05/2005 | US20050095292 Sustained release pharmaceutical compositions |
| 05/05/2005 | US20050095291 Tamper-resistant oral opioid agonist formulations |
| 05/05/2005 | US20050095290 comprising pharmacologically active substance, drug absorbefacient and taurine compound or polyamine; suppressing or preventing damage of the intestinal mucous membrane |
| 05/05/2005 | US20050095289 Drugs for disintegration on polymer to make dispersion endothermic enthalpy of solution |
| 05/05/2005 | US20050095288 Compressed core comprising guaifenesin; pseudoephedrine or phenylephrine or salt; controlled release coating |
| 05/05/2005 | US20050095287 Fosinopril composition |
| 05/05/2005 | US20050095286 Adatanserin and/or abaperidone or their salts or derivatives; high or medium viscosity hydroxypropyl methylcellulose and hydroxyethyl cellulose; anxiolytic or antidepressant agents; psychological disorders, schizophrenia; time-release agents |
| 05/05/2005 | US20050095285 Pharmaceutical composition and a process for its preparation |
| 05/05/2005 | US20050095284 Capsule having delivery port at one end; membrane plug retained in a second end remote from delivery port to provide a fluid-permeable barrier between interior and exterior; membrane plug has columnar body and slot to vent pressure to prevent expulsion; drug delivery |
| 05/05/2005 | US20050095281 Vesicle of lipid or phospholipid; and monoglyceride, fatty acid, and/or lysophospholipid active agent; preventing infection from vesicular stomatitis, visna, herpes, myxo-, lymphadenopathy associated, and/or human T-cell leukemia virus; and gonorrhea, chlamdia; time-release agents |
| 05/05/2005 | US20050095280 Cationic lipids as delivery vectors for nucleic acids, peptides and other synthetic drugs, in vitro and in vivo; form stable lamellar structures (liposomes) at physiological pH but destabilize to micelles at acidic and alkaline pH |
| 05/05/2005 | US20050095279 Transdermal analgesic systems having reduced abuse potential |
| 05/05/2005 | US20050095278 Topical drug delivery using transdermal patch; ointments, creams; oral administration |
| 05/05/2005 | US20050095277 Neuropathy cream |
| 05/05/2005 | US20050095274 Reduces waste; cleaning and hygiene of the teats and udders; dip coating and wiping operation |
| 05/05/2005 | US20050095272 Edible PGA coating composition |
| 05/05/2005 | US20050095263 Allowing full spoon filling for accurate pharmaceutical dosage; storage stability |
| 05/05/2005 | US20050095262 Multivitamin syrup for children or young adults |
| 05/05/2005 | US20050095261 Using storage stable formulation for reduction or elimination of demodex folliculorum organisms from affected skin areas |
| 05/05/2005 | US20050095246 Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators |
| 05/05/2005 | US20050095245 Topical time release dosage form; vaginal conditions |
| 05/05/2005 | US20050095232 Vaginal care composition |
| 05/05/2005 | US20050095218 Wetting and applying to hair or skin with water; rinsing |
| 05/05/2005 | US20050095216 Administering polypeptide drug that can be pegylated or conjugated to an oligomer; prodrugs, (conjugated)calcitonin or insulin; diabetes or osteoporosis treatment |
| 05/05/2005 | US20050095215 Antimicrobial shampoo compositions |
| 05/05/2005 | US20050095208 Oral care compositions for topical application |
| 05/05/2005 | US20050095207 Aerosol containing branched block copolymers comprised of acrylic acid and alkyl acrylates and/or N-alkyl or N,N-dialkylacrylamide monomers; moisture resistance |
| 05/05/2005 | US20050095206 Aerosol pharmaceutical solution formulation containing glucocorticoids stable to the storage; method for stabilizing formulations and use of a stabilizer |
| 05/05/2005 | US20050095205 Shelf life; pH stability; treating infections and inflammation |
| 05/05/2005 | US20050092969 Coating with oil or water insoluble material to make both constituents coexist in oily or aqueous medium respectively |
| 05/04/2005 | EP1528058A1 Polymorphic crystalline forms of celecoxib |
| 05/04/2005 | EP1527787A1 Immediate release tablet |
| 05/04/2005 | EP1527782A1 Nanoparticulate eplerenone compositions |
| 05/04/2005 | EP1527780A1 Stable solid formulation of enalapril salt and process for preparation thereof |
| 05/04/2005 | EP1527779A1 Sustained release ranolazine formulations |
| 05/04/2005 | EP1527775A1 Controlled release formulation containing tramadol |
| 05/04/2005 | EP1527774A1 New formulation for retinoid-containing soft gelatin capsules |
| 05/04/2005 | EP1527773A1 Pharmaceutical composition comprising sumatriptan |
| 05/04/2005 | EP1527772A1 An aerosol pharmaceutical solution formulation suitable for oral or nasal inhalation containing glucocorticoids stable to the storage; method for stabilizing formulations and use of a stabilizer |
| 05/04/2005 | EP1527771A2 Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
| 05/04/2005 | EP1527765A1 Single dose pack for curative substances for ingestion or contact |
| 05/04/2005 | EP1526880A2 Implantable or insertable medical devices for controlled drug delivery |
| 05/04/2005 | EP1526879A2 Controlled drug delivery |
| 05/04/2005 | EP1526871A1 Oral administration of calcitonin |
| 05/04/2005 | EP1526860A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 05/04/2005 | EP1526859A1 Process for preparing a sterile high molecular weight hyaluronic acid formulation |
| 05/04/2005 | EP1526858A2 Use of gaba-c receptor antagonists for the treatment of myopia |
| 05/04/2005 | EP1526855A2 Pharmaceutical compositions for the treatment of urinary incontinence |
| 05/04/2005 | EP1526853A1 Use of a papaverine-like vasodilator and pharmaceutical composition |
| 05/04/2005 | EP1526848A2 Opioid-receptor antagonists in transdermal systems having buprenorphine |
| 05/04/2005 | EP1526847A2 Pharmaceutical dosage form comprising a sulfite compound |
| 05/04/2005 | EP1526846A2 Gelatin capsule exhibiting reduced cross-linking |
| 05/04/2005 | EP1526845A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 05/04/2005 | EP1526844A2 Pellicle-resistant gelatin capsule |
| 05/04/2005 | EP1526843A1 Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
| 05/04/2005 | EP1526842A1 Processes for the preparation of oral dosage formulations of modafinil |
| 05/04/2005 | EP1526841A2 Galenic formulation for colon targeted delivery of active principles |
| 05/04/2005 | EP1526840A1 Nanoparticles for dna administration to a target organ |
| 05/04/2005 | EP1526839A1 Oral pharmaceutical forms of liquid drugs having improved bioavailability |
| 05/04/2005 | EP1526838A1 Intravenous pharmaceutical form of administration |
| 05/04/2005 | EP1526837A1 Ascorbic acid salt suspensions and use thereof as antioxidants |
| 05/04/2005 | EP1526836A1 Implantable mems medicine delivery system |
| 05/04/2005 | EP1526835A1 Injectable depot compositions and uses thereof |
| 05/04/2005 | EP1465493A4 Cultured and encapsulated pancreatic stem cells |
| 05/04/2005 | EP1424973A4 Disposal system for transdermal dosage form |
| 05/04/2005 | EP1401466B1 Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue |
| 05/04/2005 | EP1363633B1 A wet granulation process for the manufacture of pharmaceutical tablets containing paroxetine hydrochloride anhydrate |